Immune Function in Chronic Kidney Disease

Chronic Renal Disease

Volumn , Issue , 2015, Pages 285-297

  Pahl, Madeleine V ^a   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dialysis; Immunodeficiency; Infection; Inflammation; Oxidative stress

Indexed keywords

EID: 84946001626     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-411602-3.00024-X     Document Type: Chapter

References (106)

1. Carrero JJ, Stenvinkel P Inflammation in end-stage renal disease - what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
2. Girndt M, Sester U, Sester M, Kaul H, Kohler H Impaired cellular immunity in patients with endstage renal failure. Nephrol Dial Transplant 1999, 14:2807-2810.
3. Sarnak MJ, Jaber BL Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int 2000, 58:1758-1764.
4. Eleftheriadis T, Antoniadi G, Liakopoulos V, Kartsios C, Stefanidis I Disturbances of acquired immunity in hemodialysis patients. Semin Dial 2007, 20:440-451.
5. Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO Study. J Am Soc Nephrol 2003, 14:1863-1870.
6. Sarnak MJ, Jaber BL Pulmonary infectious mortality among patients with end-stage renal disease. Chest 2001, 120:1883-1887.
7. Vaziri ND, Pahl MV, Crum A, Norris K Effect of uremia on structure and function of immune system. J Ren Nutr 2012, 22:149-156.
8. Heath WR, Carbone FR Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 2009, 10:1237-1244.
9. Veldhoen M The role of T helper subsets in autoimmunity and allergy. Curr Opin Immunol 2009, 21:606-611.
10. Jameson SC, Masopust D Diversity in T cell memory: an embarrassment of riches. Immunity 2009, 31:859-871.
11. Waldschmidt T, Noelle R Immunology: Long live the mature B cell, a baffling mystery resolved. Science 2001, 293:2012-2013.
12. Herzenberg L, Haughton G, Rajewsky K CD5 B cells in development and disease. Ann NY Acad Sci 1992, 651:591-601.
13. Uckun F Regulation of human B-cell ontogeny. Blood 1990, 76:1908-1923.
14. Alexiewicz JM, Smogorzewski M, Fadda GZ, Massry SG Impaired phagocytosis in dialysis patients: studies on mechanisms. Am J Nephrol 1991, 11:102-111.
15. Massry S, Smogorzewski M Dysfunction of polymorphonuclear leukocytes in uremia: role of parathyroid hormone. Kidney Int 2001, 78:S195-S196.
16. Agrawal S, Gollapudi P, Elahimehr R, Pahl MV, Vaziri ND Effects of end-stage renal disease and haemodialysis on dendritic cell subsets and basal and LPS-stimulated cytokine production. Nephrol Dial Transplant 2010, 25:737-746.
17. Smogorzewski M, Massry SG Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int 2001, 78:S186-S189.
18. Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010, 25:205-212.
19. Moser B, Roth G, Brunner M, Lilaj T, Deicher R, Wolner E, et al. Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: a comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem Biophys Res Commun 2003, 308:581-585.
20. Yoon J, Gollapudi S, Pahl M, Vaziri N Naïve and central memory T-cell lymphopenia in endstage renal disease. Kidney Int 2006, 70:371-376.
21. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, et al. Hemodialysis associated hemosiderosis in the era of erythropoiesis-stimulating agents. Am J Med. 2012, 125:991-999.
22. Vaziri ND Understanding Iron: promoting Its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013, 61:992-1000.
23. Vaziri ND Epidemic of iron overload in dialysis population caused by intravenous iron products: a plea for moderation. Am J Med 2012, 125:951-952.
24. Farmakis D, Giakoumis A, Polymeropoulos E, Aessopos A Pathogenetic aspects of immune deficiency associated with beta-thalassemia. Med Sci Monit 2003, 9:RA19-RA22.
25. Porto G, De Sousa M Iron overload and immunity. World J Gastroenterol 2007, 13(35):4707-4715.
26. Sunder-Plassmann G, Patruta SI, Hörl WH Pathobiology of the role of iron in infection. Am J Kidney Dis 1999, 34:S25-S29.
27. Chang J, Ma JZ, Zeng Q, Cechova S, Gantz A, Nievergelt C, et al. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol 2013, 304(4):F348-F355.
28. Yoon JW, Pahl MV, Vaziri ND Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kidney Int 2007, 71:167-172.
29. Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol 2010, 31:247-254.
30. Meier P, Golshayan D, Blanc E, Pascual M, Burnier M Oxidized LDL modulates apoptosis of regulatory T cells in patients with ESRD. J Am Soc Nephrol 2009, 20:1368-1384.
31. Hendrikx TK, van Gurp EA, Mol WM, Schoordijk W, Sewgobind VD, Ijzermans JN, et al. End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+T-cells. Nephrol Dial Transplant 2009, 24:1969-1978.
32. Vaziri ND Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004, 24:469-473.
33. Vaziri ND, Navab M, Fogelman AM HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 2010, 6:287-296.
34. Vaziri ND, Norris K Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011, 31:189-196.
35. Kim HJ, Vaziri ND Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol, Renal Physiol 2010, 298:F662-F671.
36. Ruiz S, Pergola PE, Zager RA, Vaziri ND Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013, 83:1029-1041.
37. Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 2013, 28:2038-2045.
38. Vaziri ND CKD impairs barrier function and alters microbial flora of the intestine - A major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012, 21:587-592.
39. Heine GH, Ortiz A, Massy ZA, Lindholm B, Wiecek A, Martinez-Castelao A, et al. On behalf of EURECA-m working group of ERA-EDTA. monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol 2012, 8:362-369.
40. Lim WH, Kireta S, Leedham E, Russ GR, Coates PT Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients. Kidney Int 2007, 72:1138-1148.
41. Rogacev KS, Seiler S, Zawada AM, Reichart B, Herath E, Roth D, et al. CD14++CD16+monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J 2011, 32(1):84-92.
42. Pahl MV, Vaziri ND, Yuan J, Adler SG Upregulation of monocyte/macrophage HGFIN (Gpnmb/Osteoactivin) expression in end-stage renal disease. Clin J Am Soc Nephrol 2010, 5:56-61.
43. Moradi H, Ganji S, Kamanna V, Pahl MV, Vaziri ND Increased monocyte adhesion-promoting capacity of plasma in end-stage renal disease-response to antioxidant therapy. Clin Nephrol 2010, 74:273-281.
44. Ando M, Gafvels M, Bergstrom J, Lindholm B, Lundkvist I Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int 1997, 51:785-792.
45. Chmielewski M, Bryl E, Marzec L, Aleksandrowicz E, Witkowski JM, Rutkowski B Expression of scavenger receptor CD36 in chronic renal failure patients. Artif Organs 2005, 29:608-614.
46. Betjes MGH Immune cell dysfunction and inflammation in end-stage renal disease. Nat Rev Nephrol 2013, 9:255-265.
47. Girndt M, Köhler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Büschenfelde KH, Fleischer B Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995, 47:559-565.
48. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hoefsmit EC, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993, 43:641-648.
49. Betjes MG, Tuk CW, Visser CE, Zemel D, Krediet RT, Arisz L, et al. Analysis of the peritoneal cellular immune system during CAPD shortly before a clinical peritonitis. Nephrol Dial Transplant 1994, 9:684-692.
50. Sela S, Shurtz-Swirski R, Cohen-Mazor M, Mazor R, Chezar J, Shapiro G, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 2005, 16:2431-2438.
51. Pindjakova J, Griffin MD Defective neutrophil rolling and transmigrationin acute uremia. Kidney Int 2011, 80:447-450.
52. Mahajan S, Kalra OP, Asit KT, Ahuja G, Kalra V Phagocytic polymorphonuclear function in patients with progressive uremia and the effect of acute hemodialysis. Ren Fail 2005, 27:357-360.
53. Anding K, Gross P, Rost JM, Allgaier D, Jacobs E The influence of uraemia and haemodialysis on neutrophil phagocytosis and antimicrobial killing. Nephrol Dial Transplant 2003, 18:2067-2073.
54. Jaber B, Perianayagam MC, Balakrishnan VS, King AJ, Pereira BJ Mechanisms of neutrophil apoptosis in uremia and relevance of the Fas (APO-1, CD95)/Fas ligand system. J Leukoc Biol 2001, 69:1006-1012.
55. Glorieux G, Vanholder R, Lameire N Uraemic retention and apoptosis: what is the balance for the inflammatory status in uraemia?. Eur J Clin Invest 2003, 33:631-634.
56. Majewska E, Baj Z, Sulowska Z, Rysz J, Luciak M Effects of uraemia and haemodialysis on neutrophil apoptosis and expression of apoptosis-related proteins. Nephrol Dial Transplant 2003, 18:2582-2588.
57. Vaziri ND, Wang J, Cesario T, Yousefi S, Valenzuela R, Carandang G Induction, transcription, synthesis and adsorption of interleuken-1 by dialyzer membranes. J Am Soc Nephrol 1994, 4:1884-1889.
58. Klein JB, McLeish KR, Ward RA Transplantation not dialysis, corrects azotemia-dependent priming of the neutrophil oxidative burst. Am J Kidney Dis 1999, 33:483-491.
59. Hesselink DA, Betjes MG, Verkade MA, Athanassopoulos P, Baan CC, Weimar W The effects of chronic kidney disease and renal replacement therapy on circulating dendritic cells. Nephrol Dial Transplant 2005, 20:1868-1873.
60. Verkade MA, van Druningen CJ, Vaessen LM, Hesselink DA, Weimar W, Betjes MG Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant 2007, 22:128-138.
61. Mettang TP, Weber J, Machleidt C, Hübel E, Kiefer T, Kuhlmann U Epidermal Langerhans cells in uremic patients on hemodialysis or continuous ambulatory peritoneal dialysis. Nephron 1993, 65:278-283.
62. Verkade MA, van Druningen CJ, Op de Hoek CT, Weimar W, Betjes MG Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis. Clin Exp Med 2007, 7:65-71.
63. Meuer SC, Hauer M, Kurz P, Meyer zum Buschenfelde KH, Kohler H Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses. J Clin Invest 1987, 80:743-749.
64. Verkade MA, van de Wetering J, Klepper M, Vaessen LM, Weimar W, Betjes MG Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. Kidney Int 2004, 66:614-621.
65. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
66. Arina A, Murillo O, Dubrot J, Azpilikueta A, Alfaro C, Pérez-Gracia JL, et al. Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer. Expert Opin Bio Ther 2007, 5:599-615.
67. Griveas I, Visvardis G, Fleva A, Papadopoulou D, Mitsopoulos E, Kyriklidou P, et al. Comparative analysis of immunophenotypic abnormalities in cellular immunity of uremic patients undergoing either hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail 2005, 27:279-282.
68. Cala S, Mazuran R, Kordic D Negative effect of uraemia and cuprophane haemodialysis on natural killer cells. Nephrol Dial Transplant 1990, 5:437-440.
69. Vacher-Coponat H, Brunet C, Lyonnet L, Bonnet E, Loundou A, Sampol J, et al. Natural killer cell alterations correlate with loss of renal function and dialysis duration in uraemic patients. Nephrol Dial Transplant 2008, 23:1406-1414.
70. Peraldi MN, Berrou J, Dulphy N, Seidowsky A, Haas P, Boissel N, et al. Oxidative stress mediates a reduced expression of the activating receptor NKG2D in NK cells from end-stage renal disease patients. J Immunol 2009, 182:1696-1705.
71. Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D, et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012, 22:317-326.
72. Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985, 80:608-611.
73. Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012, 27:2686-2693.
74. Vaziri ND, Yuan J, Norris K Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013, 37:1-6.
75. Vaziri ND, Goshtasby N, Yuan J, Jellbauer S, Moradi H, Raffatellu M, et al. Uremic human plasma degrades intestinal epithelial barrier structure and function. Am J Nephrology 2012, 36:438-443.
76. Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S Oral activated charcoal adsorbent (AST-120) ameliorates CKD-induced intestinal epithelial barrier disruption and systemic inflammation. Am J Nephrol 2013, 37:518-525.
77. Litjens NH, van Druningen CJ, Betjes MG Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 2006, 118:83-91.
78. Betjes MG, Langerak AW, van der Spek A, de Wit EA, Litjens NH Premature aging of circulating T cells in patients with end-stage renal disease. Kidney Int 2011, 80:208-217.
79. Litjens NH, Huisman M, van den Dorpel M, Betjes MG Impaired immune responses and antigen-specific memory CD4+T cells in hemodialysis patients. J Am Soc Nephrol 2008, 19:1483-1490.
80. Betjes MG, Huisman M, Weimar W, Litjens NH Expansion of cytolytic CD4+CD28-T cells in end-stage renal disease. Kidney Int 2008, 74:760-767.
81. Yadav AK, Jha V CD4+CD28 null cells are expanded and exhibit a cytolytic profile in end-stage renal disease patients on peritoneal dialysis. Nephrol Dial Transplant 2011, 26:1689-1694.
82. Milne CD, Paige CJ IL-7: a key regulator of B lymphopoiesis. Semin Immunol 2006, 18:20-30.
83. Kalled L Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006, 18:290-296.
84. Bouts A, Davin JC, Krediet RT, Monnens LA, Nauta J, Schröder CH, et al. Children with chronic renal failure have reduced numbers of memory B cells. Clin Exp Immunol 2004, 137:589-594.
85. Fernández-Fresnedo G, Ramos MA, González-Pardo MC, de Francisco AL, Lopez-Hoyos M, Arias M B lymphopenia in uremia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant 2000, 15:502-510.
86. Mackay F, Schneider P, Rennert R, Browning J BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003, 21:231-264.
87. Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj D The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat. Rev Nephrol 2012, 8:403-412.
88. Adams JS, Hewison M Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endo Metab 2008, 4:80-90.
89. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
90. Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 1985, 134:3032-3035.
91. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A 1α,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167:4974-4980.
92. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, et al. Vitamin D3 affects differentiation, maturation, and function of human monocytederived dendritic cells. J Immunol 2000, 164:4443-4451.
93. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 2007, 178:145-153.
94. Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al. Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012, 7(7):1155-1162.
95. Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, et al. Fibroblast growth factor 23 inhibits extrrenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res 2013, 28(1):46-55.
96. Bowlus CL The role of iron in T cell development and autoimmunity. Autoimmun Rev 2003, 2:73-78.
97. Djeha A, Brock JH Uptake and intracellular handling of iron from transferrin and iron chelates by mitogen stimulated mouse lymphocytes. Biochem Biophys Acta 1992, 1133:147-152.
98. Liu JH, Liu YL, Lin HH, Yang YF, Kuo HL, Lin PW, et al. Intravenous iron attenuates postvaccination anti-HBsAg titers after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy. Int J Clin Pract 2009, 63:387-393.
99. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 2010, 17:11-16.
100. Tenopoulou M, Doulias PT, Barbouti A, Brunk U, Galaris D Role of compartmentalized redox-active iron in hydrogen peroxide-induced DNA damage and apopotosis. Biochem J 2005, 387:703-710.
101. Deicher R, Ziai F, Cohen G, Müllner M, Hörl WH High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003, 64:728-736.
102. Guo D, Jaber BL, Lee S, Perianayagam MC, King AJ, Pereira BJ, et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002, 58:134-142.
103. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND Iron sucrose impairs phagocytic function and Promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012, 36:50-57.
104. Pai AB, Conner T, McQuade CR, Olp J, Hicks P Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose. Biometals 2011, 24:603-613.
105. Sindrilaru A, Peters T, Wieschalka S, Baican C, Baican A, Peter H, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. J Clin Invest 2011, 121:985-997.
106. Betjes MG, de Wit EE, Weimar W, Litjens NH. Circulating pro-inflammatory CD4+CD28 null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrol Dial Transplant 2010; 25:3640-6.